Drug Profile
Research programme: alpha-1 antitrypsin deficiency therapy - AriZeke
Latest Information Update: 01 Nov 2006
Price :
$50
*
At a glance
- Originator AriZeke Pharmaceuticals
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency
Most Recent Events
- 01 Nov 2006 Discontinued - Preclinical for Alpha 1-antitrypsin deficiency in USA (Inhalation)
- 10 Jun 2005 Preclinical trials in Alpha 1-antitrypsin deficiency in USA (Inhalation)